Drug Profile

Long acting kallidinogenase - Jiangsu Aidea Pharmaceutical

Alternative Names: AD 018; Long acting kallikrein - Jiangsu Aidea Pharmaceutical; Long acting urokininogenase - Jiangsu Aidea Pharmaceutical

Latest Information Update: 28 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 May 2026 No recent reports of development identified for preclinical development in Stroke in China
13 Dec 2022 Preclinical trials in Stroke in China (unspecified route) as of April 2022 (Jiangsu Aidea Pharmaceutical pipeline, December 2022)
31 Dec 2021 Jiangsu Aidea Pharmaceutical has 62 patent pending and 37 patent approved as of end of 2021 (Jiangsu Aidea Pharmaceutical, December 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com